MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

NCT02250300 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: MLN9708 (2.3 mg)
DRUG: MLN9708 (4.0 mg)
DRUG: MLN9708 (3.0 mg)

Sponsor

Mehdi Hamadani